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Abstract
In the present study, a highly stable luteinizing-hormone-releasing hormone (LHRH)-conjugated PEGylated
poly(lactic-co-glycolic acid) (PLGA) nanoparticles were developed for the successful treatment of prostate cancers.
We have demonstrated that a unique combination of targeted drug delivery and controlled drug release is effective
against prostate cancer therapy. The docetaxel (DTX)/PLGA-LHRH micelles possessed a uniform spherical shape with an
average diameter of ~170 nm. The micelles exhibited a controlled drug release for up to 96 h which can minimize the
non-specific systemic spread of toxic drugs during circulation while maximizing the efficiency of tumor-targeted drug
delivery. The LHRH-conjugated micelles showed enhanced cellular uptake and exhibited significantly higher cytotoxicity
against LNCaP cancer cells. We have showed that PLGA-LHRH induced greater caspase-3 activity indicating its superior
apoptosis potential. Consistently, LHRH-conjugated micelles induced threefold and twofold higher G2/M phase arrest
than compared to free DTX or PLGA NP-treated groups. Overall, results indicate that use of LHRH-conjugated nanocarriers
may potentially be an effective nanocarrier to effectively treat prostate cancer.
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Background
Prostate cancer (PCa) is one of the most frequently diag-
nosed cancers in men (especially Western men) [1]. As
per the figures available from American Cancer Society,
nearly 230,000 new cases have been identified in the USA
alone in year 2014. This statistics is rapidly increasing with
every passing year. PCa has surpassed heart disease as the
top killer of men over the age of 85 years [2, 3]. Although
the mortality rate due to prostate gland cancer is decreas-
ing, the cost of therapy and surgery makes it costly for a
common man [4]. At present, chemotherapy and radiation
therapy are the treatments of choice for PCa; however,
current therapies are highly toxic to normal cells/tis-
sues. Especially, conventional chemotherapy results in
off targeting that could cause severe damage to rapidly
dividing cells, and patient often experiences organ
toxicity [5, 6].
In this regard, docetaxel (DTX), a taxane, remains an
important class of antitumor agents, effective against ad-
vanced prostate cancer therapy, and until recently, only
DTX-based chemotherapy is shown to be efficacious [7, 8].
However serious side effects such as myelosuppression,
neurotoxicity, acute hypersensitivity reactions, nasolacri-
mal duct stenosis, and febrile neutropenia limit its clinical
applications [9]. Additionally, solubility-related side effects
further hinder its pharmacological action, and impaired
drug delivery to tumor cells have also been shown to
promote resistance to DTX. Therefore, an effective
delivery system has to be developed to mitigate the toxicity
of DTX and to improve its chemotherapeutic efficacy
against cancers [10].
Nanoparticles loaded with various therapeutic agents
act as drug carriers that can circulate in the blood longer,
increase drug concentrations in tumors, and thus improve
the chemotherapeutic efficacy in respective cancers. In
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this regard, the number of drug delivery strategies has
been developed till date to encapsulate drug in carriers
such as polymer nanoparticles (NPs), liposomes, inclusion
complex, and self-assemblies utilizing their complex mo-
lecular structures [11, 12]. Of all, poly(lactic-co-glycolic
acid) (PLGA)-based nanoparticulate systems are reported
to be non-toxic, biodegradable, and non-immunogenic
and thus add great valuable to medical applications. Many
PLGA-based formulations are in various phases of clinical
trial [13]. The PEGylation of PLGA NP prevents the opso-
nin binding, prolongs the circulation time of nanosystems,
and could reduce the rapid uptake of reticuloendothelial
system (RES) in the blood. Again, such construct could
take advantage of enhanced permeability and retention
(EPR) effect and accumulate preferentially in tumors [14].
Targeted nanotherapies may improve therapeutic outcome
of prostate cancer treatment by selectively targeting the
receptor overexpressed in the cancer cells. Active tumor-
targeting ability could be obtained by conjugating
certain types of ligands which are specific towards the
receptor present in the cancer cells [15]. This will pave
way for high accumulation and sustained release of
therapeutic molecule in the tumor tissues. In PCa, many re-
ceptors are overexpressed including luteinizing-hormone-
releasing hormone (LHRH), prostate-specific membrane
antigen (PSMA), and epidermal growth factor receptor
(EGFR) receptors [16]. Of all LHRH, a 10-amino-acid pep-
tide hormone is the most interesting. LHRH is detected in
~85 % of PCa and has low expression in normal cell types.
Recently, LHRH and its synthetic analogs are frequently
used in the management of PCa. Especially, LHRH-R which
is the synthetic analog (to circumvent the short half-life of
natural LHRH), has been used in the present study [17].
In this study, LHRH-conjugated PEGylated PLGA
nanoparticle system was developed to encapsulate and
deliver the DTX to the prostate cancer site. We hypothe-
sized that LHRH-conjugated nanoplatform would increase
the therapeutic efficacy of DTX towards prostate cancers.
For this purpose, PEG-PLGA polymer block was synthe-
sized which was then conjugated with LHRH using
chemical reactions. Entrapment, release, and cytotoxicity
of DTX were assessed to understand the effect of
controlling drug release patterns on cellular response to
DTX-loaded LHRH-based polymeric nanoparticles. Cell
apoptosis assay and cell cycle analysis were performed to
further prove the targeting ability of ligand-directed nano-
particles towards prostate cancers.
Methods
Materials
PLGA (lactide/glycolide ratio of 50:50, carboxylic acid end
group, molecular weight, 17,000 Da) was purchased from
Sigma-Aldrich, China. The heterofunctional PEG polymer
with terminal amine and carboxylic acid functional group
(NH2-PEG-COOH) was procured from JenKem Technol-
ogy USA. LHRH analog peptide (1185 g/mol) (PYR-His-
Trp-Ser-Tyr-DLys-Leu-Arg-Pro-Gly) was purchased from
Hanhong Group (Shanghai, China). Docetaxel was ob-
tained from Sigma-Aldrich, China. All other chemicals
were reagent grade and used as such.
Formulations of Docetaxel-Loaded LHRH-Conjugated
PEGylated PLGA Nanoparticle
PLGA-PEG-COOH Conjugations
Approximately, 3 g of PLGA-COOH was dissolved in an-
hydrous methylene chloride, and to this organic solution,
70 mg of N-hydroxysuccinimide (NHS) and 140 mg of 1-
ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC) was
added. The organic mixture was stirred continuously for
12 h at room temperature. PLGA-NHS was obtained by
precipitation with cold diethyl ether (10 mL) as a white
solid, which was filtered and repeatedly washed in a cold
mixture of diethyl ether and methanol and then dried with
nitrogen and under vacuum (yield, ∼78 %). The activated
PLGA-NHS (3 g) was dissolved in anhydrous chloroform,
and to this organic solution, 0.75 g of NH2-PEG-COOH
and 40 mg of N,N-diisopropylethylamine was added and
stirred for 24 h. The resulting diblock polymer was precip-
itated by the addition of ice-cold diethyl ether, washed,
and dried.
PLGA-PEG-LHRH Conjugations
LHRH-conjugated diblock polymer was synthesized by the
addition of 100 mg of PLGA-PEG-COOH and 25 mg of
LHRH-NH2 to anhydrous methylene chloride solution.
The organic mixture was stirred for 45 min, following
which 3 mg of EDC and 1 mg of 4-dimethylaminopyridine
were added. The mixture was stirred for 48 h, purified with
dialysis, and then lyophilized.
Preparation of Drug-Loaded Nanoparticles
DTX-loaded PLGA nanoparticles were prepared by modi-
fied solvent-evaporation method [18]. Briefly, 15 mg of
DTX and 50 mg of PLGA-PEG-LHRH copolymer was dis-
solved in 6 ml of chloroform and stirred for 30 min. The
organic mixture was emulsified by adding to water (50 ml)
in a drop-wise manner. The resulting o/w emulsion was
allowed to be stirred (1000 rpm) for 3 h, and the resulting
core-shell nanoparticle was separated by dialysis method
(against water) to isolate it from the residual surfactants
and unencapsulated drug and were washed with distilled
water. The excess-free drug was separated by ultra-
centrifugation (CS150NX, Hitachi, Japan) at high speed
(500g-force) for 20 min. The supernatant was used to cal-
culate the amount of drug entrapped in the PLGA NP.
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Particle Size Analysis
The particle size and size distribution were determined
by dynamic light scattering technique using Zetasizer
NanoZS, Malvern Instruments Ltd., Malvern, UK. The
samples were diluted suitably such that the mean count
rate was approximately around 250. Each sample was
measured in triplicate.
Drug Loading and Encapsulation Efficiency
The amount of drug entrapped in the nanoparticle was
calculated by dissolving the freeze-dried NP in methanol
and sonicated for 20 min [19]. The solution was filtered,
and the filtrate was used to analyze the amount of drug
entrapped.
DL %ð Þ ¼ Weight of drug in NP=Weight of NPð Þ
 100
EE %ð Þ ¼ Actual weight of drug=Theoretical weight of drugð Þ
 100
Morphology
The morphological examination of DTX/PLGA-LHRHwas
carried out through a high-resolution transmission elec-
tron microscopy (TEM, Hitachi® 800MT, Japan). The liquid
samples were counterstained with phosphotungistic acid
and placed over a carbon-coated copper grid and air-dried.
Release Study
The release of DTX in phosphate-buffered saline was eval-
uated by a dialysis method. For this purpose, 1 mL of
DTX/PLGA-LHRH and DTX/PLGA NP suspension (2 mg
equivalent of DTX) were transferred into a dialysis tube
(molecular weight cutoff 3000, Membra-Cel®, Viskase,
USA), sealed, and placed in a tube containing 20 ml of re-
lease medium. The whole assembly was kept in a horizon-
tal laboratory shaker (100 rpm) and maintained at 37 °C.
At specific time intervals, 1 ml of sample was removed
and replaced with equal amount of fresh release medium.
The amount of drug present in the release media was ana-
lyzed using a HPLC method. A Shimadzu 510 HPLC
instrument consisted of BDS reverse phase column (150 ×
4.6 mm × 5), Shimadzu 486 tunable absorbance UV de-
tector, and SPD-10A detector, and a 20-μL Rheodyne
injection syringe was used. A freshly prepared mixture
of methanol and water (70:30 v/v) was used as a mobile
phase. Cumulative amount of drug released was evalu-
ated as the percentage of total drug release to the initial
amount.
In Vitro Cytotoxicity Assay
Human prostate cancer cell and lymph node prostate
adenocarcinoma (LNCaP) was purchased from American
Type Culture Collection (ATCC, Manassas, VA). LNCaP
was grown in RPMI 1640 culture media supplemented
with 10 % FBS and 1 % penicillin/streptomycin mixture.
The cells were incubated in ambient conditions of 37 °C
and 5 % CO2.
For cytotoxicity assay, 1 × 104 cells were seeded in a 96-
well plate and allowed to attach for overnight. The follow-
ing day, the media was replaced with fresh media and cells
were exposed with blank polymers, free DTX, DTX/PLGA
NP, and DTX/PLGA-LHRH NP and incubated for 24 h.
At the end of the experiment, the media was removed and
washed twice with PBS. The fresh media containing
0.5 mg/mL MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide) was added and incubated for
additional 3 h. The formazan crystal was extracted with
the addition of 100 μl of DMSO. The wavelength was
studied at 570 nm using a microplate reader (iMark,
Bio-Rad, USA).
Caspase-3 Activity
Caspase-3 activity was analyzed with Caspase-Glo 3 assay
kit as per manufacturer’s protocol. Cells were processed as
mentioned above, and the cells were then extracted by the
addition of 0.25 % Trypsin-EDTA digestion. The cells
were centrifuged and washed twice and re-suspended in
PBS buffer. Caspase-Glo was added to the cells and incu-
bated for 1 h at room temperature. The cell suspension
was then transferred to culture tubes and determined by
luminometer.
Cellular Uptake Study
Flow cytometry was utilized to examine the cellular up-
take of the targeted and non-targeted NPs. Rhodamine-B
was loaded in PLGA NP to observe the cellular uptake in
LNCaP prostate cancer cells. For this, the cells were
seeded in 6-well plate, and after overnight incubation, the
cells were exposed with PLGA and PLGA-LHRH formula-
tion and incubated for different time points. The cells
were then washed and extracted by trypsinization process.
The cells were then washed again with PBS (two times),
and the cells were then suspended in a flow cytometry
buffer. The amount of NP internalization was determined
using flow cytometer (BD FACSCalibur equipped with
488 and 633 nm lasers) in the FL2 channel. The experi-
ments were run in triplicate and repeated three times.
Cell Cycle Analysis
The cells were seeded in 6-well plate and treated with
respective formulations and further incubated for 24 h.
The cells were then collected by trypsinization and
centrifuged at 1500 rpm for 2 min. The cells were then
washed with ice-cold PBS buffer and stained with propi-
dium iodide and ribonuclease for 30 min. The cell cycle
was analyzed by flow cytometer (FACSCalibur flow
cytometer; BD Biosciences).
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Statistical Analysis
Data were expressed as mean ± standard deviation from
triplicate experiments and analyzed with IBM SPSS
(v 13.0; SPSS Inc, Chicago, IL). P < 0.05 was considered
statistically significant.
Results and Discussion
Chemotherapy and radiation therapy are the treatment of
choice for PCa. However, these therapies are highly toxic
to normal cells/tissues limiting its further clinical applica-
tion. Docetaxel (DTX), a taxane, is indicated in advanced
prostate cancer therapy as a first-line therapy agent, and
therefore, an effective delivery system has to be developed
to mitigate the toxicity of DTX and to improve its chemo-
therapeutic efficacy against cancers. The present study is
an attempt to encapsulate and deliver the DTX to the pros-
tate cancer site using a novel LHRH-conjugated PEGylated
PLGA nanoparticle system. We hypothesized that LHRH-
conjugated nanoplatform would increase the therapeutic
efficacy of DTX towards prostate cancers. LHRH, which is
a 10-amino-acid peptide hormone is detected in ~85 % of
PCa and have low expression in normal cell types. For
this purpose, PLGA-COOH was activated by carbodii-
mide/NHS-mediated chemistry and then conjugated
with heterofunctional PEG, NH2-PEG-COOH. The
diblock polymer PLGA-PEG-COOH was then conju-
gated with LHRH (Fig. 1).
Particle Size and Morphological Analysis
The DTX and PLGA-PEG-LHRH were self-assembled to
form a stable drug-loaded micellar architecture. The
particle size of PLGA-LHRH was found to be around
~170 nm with an excellent dispersity index of 0.15 (PDI)
(Fig. 2a). A size of less than <200 nm is clinically relevant
for passive tumor targeting via EPR [20]. To study the
stability of the PLGA-LHRH micelles, the size and size
distribution of the freshly prepared micelles and micelles
stored in 4 °C for 1–2 months were also observed (data
not shown). The size was almost the same even when
stored for a prolonged period of time. Here in this study,
surface modifications of PLGA NP with PEG are expected
to reduce non-specific interactions with RES systems and
prolong the blood circulation time.
The TEM image clearly showed spherical nature of the
drug-loaded micellar structures. The average diameter
ranged from 150 to 200 nm and uniformly dispersed on
the carbon-coated copper grids, and no aggregation was
observed (Fig. 2b). The sizes of the drug-loaded micelles
measured by TEM were smaller than those measured by
DLS because TEM measures the size of the dried micelles
while DLS measures the hydrodynamic diameters of the
micelles. The stability was further assessed by freeze
drying process. The nanoparticles were freeze dried with
various amounts of trehalose (as a cryoprotectant) and
then reconstituted (Fig. 2c). The particle size significantly
increased in the absence of cryoprotectant while addition
of trehalose did reduce the size below 300 nm; 5 % trehal-
ose was observed to be optimal as the size of particles
were almost equal to that of control (liquid dispersion)
while further increase in the percentage of trehalose did
not have any influence. The nanoparticles also exhibited a
long-term storage stability indicating its excellent stability
(Fig. 2d).
The amount of drug entrapped in the micelles was de-
termined by HPLC technique. The entrapment efficiency
was more than 85 % while the actual drug loading was
more than >25 % w/w. The high drug loading capacity
of delivery system has clinical relevance.
Fig. 1 Schematic illustration of formulation of docetaxel-loaded polymeric micelles. PLGA-PEG was conjugated with LHRH moiety via standard
carbodiimide/NHS-mediated chemistry. The PLGA-PEG-LHRH and docetaxel was self-assembled to form core-shell nanoparticles
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In Vitro Drug Release Study
The release profile of DTX (Fig. 3a) from PLGA and
PLGA-LHRH micelles were studied at phosphate-
buffered saline (pH 7.4) at 37 °C. As shown in Fig. 3b,
a sustained release of DTX was observed from the
micelles throughout the study period. No sign of ini-
tial burst release was observed indicating that the
drug was stably incorporated in the core of the mi-
celles. Similarly, LHRH conjugation also has no effect
on the overall release rate as the release from both
the micelles was almost similar throughout the study
period. For example, nearly ~25 % of DTX released
from both the micelles at the end of 24 h, while
nearly 80–85 % of drug release by the end of 96 h of
study period. Such release profile will be very efficacious
from tumor targeting perspective. A delivery system which
can release the drug in a controlled rate in the physio-
logical conditions is most desirable for the tumor targeting
as it will have greater chance to accumulate in the tumor
tissues and effectively minimize the drug-related systemic
toxicity [21].
Cellular Uptake
The effect of LHRH was investigated by studying the
cellular internalization of rhodamine-B loaded targeted
and non-targeted PLGA micelles in LNCaP cancer cells.
LNcaP is reportedly overexpress LHRH receptors than
when compared to normal cell lines [22]. In this study, the
cellular uptake of rhodamine-loaded non-conjugated or
conjugated micelles was evaluated by flow cytometer
analysis. As shown in Fig. 4, significant difference in fluor-
escence intensities was observed between two groups. At
the end of 1 h, nearly 1.5-fold higher cellular internaliza-
tion was observed for PLGA-LHRH micelles than when
compared with non-targeted PLGA micelles. The cellular
uptake increased in a time-dependent manner, and nearly
twofold increased uptake was seen with the targeted
micelles. It could be expected that nanocarriers were inter-
nalized via endocytosis mechanism wherein the micelles
will reside in the cytoplasmic region at first, following
which, drug will be released and reach the nuclear or peri-
nuclear region. It is well known that insufficient cellular
internalization of a drug-loaded NPs leads to suboptimal
Fig. 2 a Particle size distribution of PLGA-LHRH micelles measured by dynamic light scattering technique. b Transmission electron microscope
image of PLGA-LHRH. c Solid state stability analysis. d Storage stability study
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intracellular drug concentration, less effective cancer
therapy, and the potential for drug resistance. Similarly,
higher cellular internalization will further improve the
chemotherapeutic efficacy [23].
Anticancer Effect of Non-Targeted and Targeted Micelles
We next sought to determine the anticancer effect of free
DTX, non-targeted DTX/PLGA NP, and DTX/PLGA-
LHRH NP in LNCaP prostate cancer cells. At first, toxicity
of blank polymer was tested at various concentrations. As
seen (Fig. 5a), blank polymer showed showed high cell
viability even at maximum tested concentrations indicat-
ing its non-toxic profile. Such delivery system will be very
ideal of cancer-targeting purposes. Upon treatment with
free DTX, DTX/PLGA, and DTX/PLGA-LHRH NP, a typ-
ical dose-dependent cytotoxicity was observed after 24 h
incubation. Most notable observation is the anticancer ef-
fect of LHRH-conjugated micelles. It is clearly evident that
Fig. 3 a HPLC chromatogram of DTX. b In vitro release profile of DTX from PLGA and PLGA-LHRH micelles. The release study was performed in
phosphate buffered saline (PBS; pH 7.4) at 37 °C
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LHRH conjugation to the NP surface greatly increased the
cellular uptake and therefore increased the cell cytotox-
icity. For example, at a dose of 5 μg/ml, the cell viability of
DTX, DTX/PLGA, and DTX/PLGA-LHRH NP treated
groups were 50.26, 43.28, and 30.34 % compared to that
of control. Furthermore, IC50 value was calculated to
quantify the individual effect of formulations on the can-
cer cells. It was observed that the IC50 value of DTX, DTX/
PLGA, and DTX/PLGA-LHRH NP were 4.98, 3.95, and
1.28 μg/ml, respectively. The superior performance of tar-
geted micelles was attributed to its specific affinity towards
the LHRH receptors overexpressed in cancer cells and due
to the enhanced cellular uptake. The low cytotoxicity ex-
hibited by the non-targeted micelles may be attributed to
their lower level of cellular uptake in comparison to that
of the targeted micelles [24]. Our study confirms that the
targeted delivery of bioactive agents results in enhanced
efficacy in PCa therapy.
Caspase-3 Activity
Consistent with the in vitro cytotoxicity assay, caspase-3
activity was evaluated in all aforementioned groups. As
shown in Fig. 5b, LHRH-conjugated micelles induced
significantly higher cell apoptosis than other groups.
PLGA-LHRH exhibited threefold higher apoptosis than
compared to free DTX treated cancer cells. Caspase-3
bring a crucial apoptosis marker; results suggest that
Fig. 4 Cellular uptake of PLGA NP and PLGA-LHRH micelles in LNCaP prostate cancer cells. Cellular uptake was recorded byflow cytometry analysis on
a BD FACS caliber. Rhodamine-B was used as a fluorescent moiety and incorporated in the nanocarriers
Fig. 5 a Effect of free DTX, PLGA NP, and PLGA-LHRH micelles on the cellular viability of LNCaP prostate cancer cells. LNCap cells were
treated with formulations and incubated for 24 h, and cell viability was determined by MTT assay. b Caspase-3 activity after treating with
respective formulations
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surface conjugation of targeting ligand will be detrimental
to cancer cells.
Apoptosis Analysis
The apoptosis analysis was evaluated by means of
Annexin-V/PI-based apoptosis kit. The apoptosis analysis
was presented in Fig. 6 (X and Y axis shows the FITC and
PI emissions). As seen, all the formulations exhibited
considerable apoptosis of cancer cells after 24 h incu-
bation. Free DTX induced nearly ~25 % of apoptosis
(early and late apoptosis), whereas PLGA NP induced
a ~56 % of apoptosis indicating the advantage of
nanoparticles. Importantly, the presence of LHRH
receptor greatly increased the fraction of apoptosis
cells. As seen, approximately 62 % of cancer cells
underwent apoptosis.
Cell Cycle Analysis
Flow cytometer analysis was carried out to determine
the effect of targeted and non-targeted micelles on the
cell cycle progression of LNCaP cells (Fig. 7). The re-
sults clearly showed that DTX and its formulations
caused the cell death by a typical G2/M phase arrest.
Specifically, LHRH-conjugated micelles induced three-
fold and twofold higher G2/M phase arrest than
compared to free DTX or PLGA NP-treated groups.
PLGA-LHRH exhibited nearly 60 % G2/M phase arrest
than 30 % by PLGA NP. Notably, targeted micelles
exhibited nearly ~15 % of cell death (subG0) than
other groups. In general, DTX-loaded NP induce
mitotic arrest by the release of drug which produces
unstable microtubule, interfering with the mitotic spindle
function, thereby arresting the cells in the G2/M phase of
mitosis [25]. The results therefore suggest that targeted
NPs kill the cancer cells more efficiently than the non-
targeted NPs.
Conclusions
In conclusion, we have successfully developed LHRH-
conjugated PEGylated PLGA nanoparticles for the
treatment of prostate cancers. The diblock polymers
were synthesized and conjugated to LHRH by carbo-
diimide chemistry. A unique combination of targeted
drug delivery and controlled drug release was proven
to be effective against prostate cancer therapy. The
PLGA-LHRH micelles possessed a uniform spherical
shape with an average diameter of ~170 nm. The micelles
exhibited a controlled drug release for up to 96 h which
can minimize the non-specific systemic spread of toxic
drugs during circulation while maximizing the efficiency
of tumor-targeted drug delivery. The LHRH-conjugated
micelles showed enhanced cellular uptake and exhibited
significantly higher cytotoxicity against LNCaP cancer
cells. We have showed that PLGA-LHRH induced
greater caspase-3 activity indicating its superior
apoptosis potential. Consistently, LHRH-conjugated
micelles induced threefold and twofold higher G2/M
phase arrest than compared to free DTX or PLGA
NP-treated groups. Overall, results indicate that use
of LHRH-conjugated nanocarriers could be an effect-
ive approach to target and kill prostate cancer cells.
Additional studies, however, are required to further
confirm the therapeutic potency of present delivery
system.
Fig. 6 Annexin V/PI-based apoptosis analysis on prostate cancer cells
Fig. 7 Cell cycle progression of LNCaP after treating with free DTX,
PLGA NP, and PLGA-LHRH micelles
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